Mavoglurant

Drug Profile

Mavoglurant

Alternative Names: AFQ-056

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Alkynes; Antiparkinsonians; Anxiolytics; Esters; Indoles; Nitriles; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obsessive-compulsive disorders
  • No development reported Chorea; Gastro-oesophageal reflux; Smoking withdrawal
  • Discontinued Anxiety disorders; Drug-induced dyskinesia; Fragile X syndrome

Most Recent Events

  • 03 Oct 2016 Novartis plans a phase II trial for Fragile X Syndrome (Children) in USA (NCT02920892)
  • 09 Jun 2016 Novartis terminates a phase-II clinical trials in Obsessive-compulsive disorders in USA, Bulgaria, Czech Republic, Poland, Switzerland, United Kingdom and Germany as the study did not meet its primary efficacy objective(NCT01813019)
  • 11 Apr 2016 Novartis terminates phase II trial in Fragile X syndrome in in USA, Australia, Canada, Denmark, France, Germany, Italy, Spain and Switzerland (NCT01348087)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top